US Patent

US8501228 — Stable compositions of famotidine and ibuprofen

Method of Use · Assigned to Horizon Pharma USA Inc · Expires 2026-07-18 · 0y remaining

Vulnerability score 85/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects stable pharmaceutical compositions of famotidine and ibuprofen in a single unit dosage form.

USPTO Abstract

Stable pharmaceutical compositions of famotidine and ibuprofen in a single unit dosage form are disclosed herein. The compositions comprise a famotidine core having a reduced or minimal surface area surrounded by a layer of ibuprofen. In some embodiments, the ibuprofen is in direct physical contact with the famotidine.

Drugs covered by this patent

Pepcid (famotidine) · Generic (originally Yamanouchi/Merck)

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-1196`	—	Pepcid

Patent Metadata

Patent number: US8501228
Jurisdiction: US
Classification: Method of Use
Expires: 2026-07-18
Drug substance claim: No
Drug product claim: No
Assignee: Horizon Pharma USA Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.